24-GI-134-MSD (015-00):A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician s Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma,Gastroesoph

Grants and Contracts Details

StatusActive
Effective start/end date6/27/246/27/26

Funding

  • Merck Sharp & Dohme Corporation: $2.00